JUL 20, 2019 07:27 AM PDT

New hope for ovarian cancer

Ovarian cancer affects roughly 1 in 78 women and although survival rates are high (over 90%) with early diagnosis, we currently do not have a way to test for early detection and thus early diagnosis only occurs in around 20% of cases. That means that most women don’t discover their disease until it has already started spreading, making it much harder to treat. But new research focusing on high-grade serous ovarian cancer, which is the most common form of ovarian cancer, offers hope for alternative treatments.

The research was published recently in the journal Molecular Cancer Research and suggests that blocking a particular enzyme called isocitrate dehydrogenase 1 (IDH1) could deter the proliferation of high-grade serous ovarian cancer cells, essentially by putting the cancer cells into early senescence and making it impossible for them to grow and multiply.

"One of the biggest problems of cancer cells," says senior study author Katherine M. Aird Ph.D., assistant professor of cellular and molecular physiology at Penn State College of Medicine in Hershey, PA, "is they can grow forever without stimulus. By inducing senescence, the cells can no longer divide and grow," she adds.

Dr. Aird and her colleagues arrived at this conclusion after analyzing the ways that healthy and cancerous fallopian tube cells use sugar. Implementing mass spectrometry, the team found that while the cancer cells tended to use sugar in the citric acid cycle, the healthy cells usually converted sugar to lactate through aerobic glycolysis.

This is exactly why many cancer treatments target glycolysis – but in the process, these treatments risk damaging healthy cells as well. The IDH1 enzyme, on the other hand, is critical to the citric acid cycle, and blocking it could provide alternative treatment methods that specifically target cancer cells.

New research could lead to alternative treatments for ovarian cancer. Photo: Pixabay

As Medical News Today reports, the need for new treatments can target later stages of the ovarian cancer is of utmost urgency. “Around 70% of those with high-grade serous ovarian cancer will experience relapse because the cancer has a tendency to develop resistance to chemotherapy. There is an urgent need for new approaches to treating this disease.”

Dr. Aird hopes this finding will lead to those alternative treatments, saying "One of our long term goals is to try and repurpose this already approved drug as a treatment for this form of ovarian cancer.” According to her, the FDA has already approved a drug that specifically targets the IDH1 enzyme.

Sources: Medical News Today, Molecular Cancer Research

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
AUG 23, 2019
Drug Discovery
AUG 23, 2019
First PI3K Inhibitor for Breast Cancer
The U.S. Food and Drug Administration has approved Piqray (alpelisib) tablets, to be used in conjunction with FDA-approved endocrine therapy fulvestrant fo...
AUG 23, 2019
Cancer
AUG 23, 2019
New discovery sheds light for precision medicine in cancer
A recent study published in Cancer Research highlights findings of a molecular indicator that could provide a new way for doctors to help predict how patie...
AUG 23, 2019
Cancer
AUG 23, 2019
Will Light Therapy Edge Out Opioids for Cancer Mouth Pain?
Photobiomodulation therapy, a form of low-dose light therapy, has now been found to be one of the best ways to treat the pain of oral mucositis, the mouth ...
AUG 23, 2019
Drug Discovery
AUG 23, 2019
Treating Drug-Resistant Acute Lymphoblastic Leukemia
New therapeutics may have helped improve survival rates for acute lymphoblastic leukemia patients but some patients still remain unresponsive to existing t...
AUG 23, 2019
Clinical & Molecular DX
AUG 23, 2019
New Device Improves Accuracy In Lung Cancer Diagnosis
Acute respiratory distress syndrome ARDS occurs when fluid builds up in the alveoli. These tiny elastics sacs, which are responsible for gaseous exchange i...
AUG 23, 2019
Cancer
AUG 23, 2019
Antibiotic use associated with bowel cancer
From 2000–2010, global consumption of antibiotics rose by 35% up to 70 billion doses each year. Although doctors are more cautious to prescribe antib...
Loading Comments...